SORRENTO THERAPEUTICS INC

Inactive Instrument

Analyst Reco. Sorrento Therapeutics Inc Other OTC

Equities

US83587F1030

End-of-day quote Other OTC Other stock markets
- ^USD	-

Mar. 15	Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	MT
Mar. 12	News Highlights : Top Company News of the Day - Tuesday at 5 AM ET	DJ

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Dawson James Downgrades Sorrento Therapeutics to Neutral Rating From Buy	23-02-13	MT
Cantor Fitzgerald Initiates Sorrento Therapeutics at Overweight With $5 Price Target	22-11-02	MT
HC Wainwright Adjusts Sorrento Therapeutics' Price Target to $20 From $26, Reiterates Buy Rating	22-03-25	MT
SORRENTO THERAPEUTICS : HC Wainwright Adjusts Sorrento Therapeutics' Price Target to $26 From $30, Keeps Buy Rating	21-08-09	MT
Sorrento Therapeutics, Inc. Announces Positive Results of Phase 1b Study of COVI-MSC Treatment of ICU Covid-19 Patients, Achieving 100% (10 out 10) Discharge Rate	21-04-20	CI
SORRENTO THERAPEUTICS : B. Riley Starts Sorrento Therapeutics at Buy With $26 Price Target	21-01-29	MT
SORRENTO THERAPEUTICS : Alliance Global Partners Starts Sorrento Therapeutics at Buy With $35 Price Target	21-01-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+201.5% on SUPER MICRO COMPUTER since our purchase on February 17, 2023

Replicate our performance

fermer